Strata Critical Medical, Inc.: insider trades · United States · SEC (Form 4)

About Strata Critical Medical, Inc.

Strata Critical Medical, Inc. (NASDAQ: SRTA) is a United States-based, New York-headquartered company focused on time-critical logistics and medical services for the U.S. healthcare market. The company, formerly known as Blade Air Mobility, Inc., underwent a major strategic reset in 2025 after divesting its legacy passenger transportation business. Following that transaction, Strata emerged as a more focused, contract-driven “pure play” medical logistics and clinical services platform, with a business model that is less exposed to consumer travel demand and more anchored to healthcare infrastructure. Strata’s core offering is built around integrated solutions for transplant hospitals and organ procurement organizations. The company provides an end-to-end “one call” solution that can include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion, preservation services, and related coordination support. These capabilities are delivered primarily through the Trinity Medical Solutions and Keystone Perfusion Services brands. In addition, Strata offers perfusion staffing and equipment solutions for cardiovascular surgery centers, broadening its addressable market beyond transplant-related procedures. From a competitive standpoint, Strata operates in a specialized niche, but one with favorable structural dynamics. Demand is supported by the persistent shortage of donor organs, the operational complexity of transplant logistics, and the need to reduce time-sensitive delays across the care pathway. The company’s main differentiator is its integrated service model, which combines transportation, clinical coordination, and procedure execution within a single platform. Management has described Strata as operating one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations in the United States, which suggests a meaningful network position in a highly specialized segment. Geographically, the business is primarily domestic and centered on the United States, where Strata also maintains its principal executive offices in New York. The company is not positioned as a broad international operator; instead, its strategy appears focused on deepening its U.S. footprint and expanding within adjacent medical-critical workflows. Recent corporate milestones have been important for equity investors. In August 2025, Strata completed the sale of its Passenger business to Joby Aviation, formally closed the strategic transition, and began trading under the new ticker SRTA on NASDAQ. In September 2025, the company completed the acquisition of Keystone Perfusion Services, strengthening its capabilities in organ recovery, normothermic regional perfusion, and perfusion-related medical services. More recently, the company reported strong 2025 operating momentum in its 2026 disclosures, including revenue growth and improved guidance, which points to a more streamlined business profile and a clearer earnings narrative centered on critical healthcare services.